Medication Use Evaluation of Fecal Microbiota Spores (live-brpk) for the Prevention of Recurrent Clostridioides difficile Infection.

Authors

Haley Michaud PharmD, Parkview HealthFollow
Trent Towne PharmD, BCPS, Parkview HealthFollow
Sarah Ferrell PharmD, BCPPS, Parkview HealthFollow
Bhavika Patel PharmD, Parkview HealthFollow
Noah Budi PharmD, Parkview HealthFollow

Abstract

Presented at the ASHP Midyear Clinical Meeting. New Orleans, LA

This medication use evaluation found that infectious diseases providers were more likely to prescribe advanced treatments such as fidaxomicin or fecal microbiota compared to other specialties. Of the 93.1% of patients seen by Infectious Disease, 62.9% (n=17) of those patients were prescribed fecal microbiota spores (live-brpk) (VOWST). Of the 29 eligible patients, 41.4% (n=12) were identified as missed opportunities.

Document Type

Poster

Publication Date

12-2024

Recommended Citation

Michaud, Haley PharmD; Towne, Trent PharmD, BCPS; Ferrell, Sarah PharmD, BCPPS; Patel, Bhavika PharmD; and Budi, Noah PharmD, "Medication Use Evaluation of Fecal Microbiota Spores (live-brpk) for the Prevention of Recurrent Clostridioides difficile Infection." (2024). Pharmacy Residency. 33.
https://researchrepository.parkviewhealth.org/pharmresidency/33